Met receptor tyrosine kinase: enhanced signaling through adapter proteins
- PMID: 11114738
- DOI: 10.1038/sj.onc.1203859
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Abstract
The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ligand for Met is hepatocyte growth factor/scatter factor (HGF/SF) and while normal HGF/SF-Met signaling is required for embryonic development, abnormal Met signaling has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. Following ligand binding and autophosphorylation, Met transmits intercellular signals using a unique multisubstrate docking site present within the C-terminal end of the receptor. The multisubstrate docking site mediates the binding of several adapter proteins such as Grb2, SHC, Crk/CRKL, and the large adapter protein Gab1. These adapter proteins in turn recruit several signal transducing proteins to form an intricate signaling complex. Analysis of how these adapter proteins bind to the Met receptor and what signal transducers they recruit have led to more substantial models of HGF/SF-Met signal transduction and have uncovered new potential pathways that may be involved into Met mediated tumor cell invasion and metastasis.
Similar articles
-
Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.Mol Cancer Res. 2006 Jul;4(7):499-510. doi: 10.1158/1541-7786.MCR-05-0141. Mol Cancer Res. 2006. PMID: 16849525
-
HGF/SF-met signaling in the control of branching morphogenesis and invasion.J Cell Biochem. 2003 Feb 1;88(2):408-17. doi: 10.1002/jcb.10358. J Cell Biochem. 2003. PMID: 12520544 Review.
-
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.Cancer Res. 2005 Oct 15;65(20):9355-62. doi: 10.1158/0008-5472.CAN-05-1946. Cancer Res. 2005. PMID: 16230398
-
Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3.J Cell Biochem. 2005 Jul 1;95(4):805-16. doi: 10.1002/jcb.20459. J Cell Biochem. 2005. PMID: 15838885
-
The shadow of death on the MET tyrosine kinase receptor.Cell Death Differ. 2008 Mar;15(3):427-34. doi: 10.1038/sj.cdd.4402229. Epub 2007 Oct 5. Cell Death Differ. 2008. PMID: 17917681 Review.
Cited by
-
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Diagn Pathol. 2015 Jul 28;10:130. doi: 10.1186/s13000-015-0362-5. Diagn Pathol. 2015. PMID: 26215852 Free PMC article.
-
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.Int J Clin Oncol. 2013 Apr;18(2):207-13. doi: 10.1007/s10147-011-0361-9. Epub 2012 Jan 5. Int J Clin Oncol. 2013. PMID: 22218908
-
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma.Cancer Res Treat. 2020 Apr;52(2):481-491. doi: 10.4143/crt.2019.370. Epub 2019 Oct 24. Cancer Res Treat. 2020. PMID: 31645095 Free PMC article.
-
HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers.Int J Mol Sci. 2018 Oct 23;19(11):3295. doi: 10.3390/ijms19113295. Int J Mol Sci. 2018. PMID: 30360560 Free PMC article. Review.
-
Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease.Stem Cell Res Ther. 2014 May 28;5(3):70. doi: 10.1186/scrt459. Stem Cell Res Ther. 2014. PMID: 24886681 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
